Medical Advocates
Efavirenz/Tenofovir/Emtricitabine (Atripla)
 
Main Page

New and Noteworthy
FDA Updates
Journal Citations
Pediatric Updates
Product Information







 
ARV Drugs Main Page Main New/Newsworthy Home Page      
This web page is best viewed by using INTERNET EXPLORER
Last Update:  February 28, 2010  
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
February 2010
 
17th CROI Citations
 
  • POSTER
     Assessment of Bioequivalence of Tenofovir, Emtricitabine, and Efavirenz (Atripla) Fixed-dose
    Combination Tablet Compared with a Compounded Oral Liquid Formulation Derived from the Tablet
    J King, M McCall, A Cannella
    PDF Poster         Abstract
  • POSTER
    A One-pill, Once-daily Fixed-dose Combination of Efavirenz, Emtricitabine, and Tenofovir Disoproxil
    Fumarate Regimen Is Associated with Higher Unannounced Pill Count Adherence than Non-one-pill,
    Once-daily Regimens
    D Bangsbe, K Ragland, A Monk, et al
    PDF Poster         Abstract
FDA Updates
     
Journal Citations
     
General Reports
 
 
Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of
patients infected with HIV-1.
 Oyagüez I, Casado MA, Cotarelo M, et al.
 Farm Hosp. 2009 Sep 1;33(5):247-56
 Abstract

Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify
ongoing therapy just to use one less tablet.
[No authors listed] 
Prescrire Int. 2009 Jun;18(101):105.
 Abstract

A WEEK IN REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
Atripla - HIV therapy in one pill.
 Julg B, Bogner JR.   
 Ther Clin Risk Manag. 2008 Jun;4(3):573-7.
 Paper
 
A WEEK IN REVIEW FEATURED REPORT
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in
combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
 Sánchez-de la Rosa R, Herrera L, Moreno S.
 Clin Ther. 2008 Feb;30(2):372-81.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
 Killingley B, Pozniak A.  
 Drugs Today (Barc). 2007 Jul;43(7):427-42
 Abstract

Bioequivalence of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet
Regimen.
 Mathias AA, Hinkle J, Menning M, et al 
J Acquir Immune Defic Syndr. 2007 Jul 19;
 Abstract

Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate: triple combination tablet.
 Frampton JE, Croom KF. 
Drugs. 2006;66(11):1501-12
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
 Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/
Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and
Morphologic Changes: A 96-Week Analysis.
 Pozniak AL, Gallant JE, Dejesus E, et al  
J Acquir Immune Defic Syndr. 2006 Oct 12;
 Abstract
 

Efficacy
 
 
Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify
ongoing therapy just to use one less tablet.
 [No authors listed] 
Prescrire Int. 2009 Jun;18(101):105.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Simplification of Antiretroviral Therapy to a Single-Tablet Regimen Consisting of Efavirenz, Emtricitabine,
and Tenofovir Disoproxil Fumarate Versus Unmodified Antiretroviral Therapy in Virologically Suppressed
HIV-1-Infected Patients.
 Dejesus E, Young B, Morales-Ramirez JO, et al
J Acquir Immune Defic Syndr. 2009 Apr 7.
Abstract
 
FULL-TEXT ARTICLE
 Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected
patients in Western India.
 Pujari S, Dravid A, Gupte N, et al 
Medscape J Med. 2008;10(8):196.
 Paper
Pediatric Data
 
USPHS Pediatric Antiretroviral Drug Information
 US Treatment Guidelines

ARV Drugs Main Page Main New/Newsworthy Home Page      

Efavirenz/Emtricitabine/Tenofovir (Atripla)